预约演示

更新于：2025-07-02

Cabozantinib (s)-Malate

苹果酸卡博替尼

更新于：2025-07-02

概要

基本信息

药物类型

小分子化药

别名

cabozantinib、Cabozantinib Malate、Cabozantinib s-malate (USAN)

+ [9]

靶点

AXL x RET x ROS1 x TYRO3 x Tie-2 x TrkB x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit x c-Met

作用方式

抑制剂、拮抗剂

作用机制

AXL抑制剂(AXL受体酪氨酸激酶抑制剂)、RET抑制剂(酪氨酸蛋白激酶受体RET抑制剂)、ROS1抑制剂(原癌基因酪氨酸蛋白激酶ROS抑制剂)

治疗领域

肿瘤消化系统疾病内分泌与代谢疾病+ [11]

在研适应症

胰腺外神经内分泌肿瘤胰腺神经内分泌肿瘤分化型甲状腺癌+ [191]

非在研适应症

晚期胆管癌晚期乳腺癌肝外胆管癌+ [40]

原研机构

Exelixis, Inc.

在研机构

National Cancer Institute

Exelixis, Inc.

Bristol Myers Squibb Co.

+ [19]

非在研机构

University of Washington

EMD Serono, Inc.

江苏豪森药业集团有限公司

权益机构

Ipsen SA

Takeda Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

+ [7]

最高研发阶段批准上市

首次获批日期

美国 (2012-11-29),

甲状腺髓样癌

最高研发阶段(中国)临床3期

特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)、孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C32H30FN3O10

InChIKeyHFCFMRYTXDINDK-WNQIDUERSA-N

CAS号1140909-48-3

关联

268

项与苹果酸卡博替尼相关的临床试验

NCT06811116

/ Recruiting临床1/2期IIT

A Phase I/II Trial of Sapanisertib in Combination With Cabozantinib in β-Catenin-Mutated Hepatocellular Carcinoma

This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contains a mutation (change) in the β-catenin gene. Sapanisertib and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sapanisertib and cabozantinib together may work better than giving cabozantinib alone in treating β-catenin-mutated metastatic hepatocellular carcinoma.

开始日期2026-02-10

申办/合作机构

National Cancer Institute

NCT06900595

/ Not yet recruiting临床2期IIT

A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with cemiplimab may kill more tumor cells in patients with locally advanced unresectable or recurrent/metastatic adrenocortical cancer.

开始日期2025-07-31

申办/合作机构

National Cancer Institute

NCT06502171

/ Not yet recruiting临床1期IIT

A Phase 1/1b/2 Study of Cabozantinib in Combination With Selumetinib for Plexiform Neurofibroma in Adults and Adolescents With Neurofibromatosis Type 1

Based on the clinical activity of both selumetinib and cabozantinib as monotherapies in clinical trials, the demonstrated activity of these agents in reduced doses in preclinical studies, and the non-overlapping toxicity profiles, the study will assess the tolerability and efficacy of selumetinib and cabozantinib in combination in participants with NF1 ≥16 years old with progressive and/or symptomatic PN in a phase 1/1b/2 clinical trial.
Trial Design Phase 1 This will be an open label, dose escalation phase. Dose level escalation will be determined by a rolling six design. In this design, up to 6 participants can be enrolled at a given dose level and then evaluated for dose limiting toxicity (DLT) within the DLT window. The DLT window is defined as 16 weeks in this study based on the long half-life of cabozantinib and the desire to have maximum confidence about long-term tolerability of the combination prior to proceeding to the next dose level.
Phase 1b Once the recommended phase 2 dose has been determined in phase 1, an expanded cohort of 12 participants will be enrolled in phase 1b portion of the study.
Phase 2 This will be an open label, single-arm phase using the recommended phase 2 dose.

开始日期2025-07-01

申办/合作机构

The University of Alabama at Birmingham

[+2]

100 项与苹果酸卡博替尼相关的临床结果

登录后查看更多信息

100 项与苹果酸卡博替尼相关的转化医学

登录后查看更多信息

100 项与苹果酸卡博替尼相关的专利（医药）

登录后查看更多信息

2,692

项与苹果酸卡博替尼相关的文献（医药）

2025-08-01·Clinical Genitourinary Cancer

Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project

Article

作者: Lacek, Michal ; Poprach, Alexandr ; Domański, Piotr ; Bezděková, Monika ; Kopecky, Jindrich ; Richter, Igor ; Kolaríková, Eva ; Sikora-Kupis, Bożena ; Pinto, Alvaro ; Studentova, Hana ; Koloušková, Ivana ; Buchler, Tomas ; Fiala, Ondrej ; Kucharz, Jakub ; Darewicz, Marta

INTRODUCTION:

The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically in the last few years, with different options being available, and with no data comparing these new systemic therapies. Therefore, the value of real-world outcomes (RWO) becomes of great interest to understand the effectiveness of these treatments. Here we analyze the outcome of metastatic RCC patients treated with first-line cabozantinib in a retrospective cohort from the Czech Republic and Poland METHODS: Patients with metastatic RCC treated with first-line cabozantinib in the Czech Republic and Poland were included in a retrospective fashion. Data were collected regarding progression-free survival (PFS), overall survival (OS), response rate and toxicity, with a focus in several subgroups of interest.

RESULTS:

We identified 146 patients, the majority of them (80.8%) with clear cell RCC (ccRCC). The median OS was 14.7 months, and the median PFS 8.2 months, with a response rate of 30.3%. CTCAE v3.0 grade 3+4 toxicity was presented in 34.2% of patients. The efficacy of Cabozantinib was maintained regardless of histologic subtype and the presence of sarcomatoid component, although PFS and OS data were numerically better for nonclear cell RCC. Bone and liver metastases were confirmed as independent factor for poor survival in the multivariate analysis.

CONCLUSIONS:

In our series, Cabozantinib demonstrated its activity in RCC patients in a RWO setting. Our data can be considered comparable with what has been seen in randomised clinical trials, considering the inherent bias present in RWO studies.

2025-07-01·COMPUTERS IN BIOLOGY AND MEDICINE

Computer-aided drug discovery of a dual-target inhibitor for ovarian cancer: therapeutic intervention targeting CDK1/TTK signaling pathway and structural insights in the NCI-60

Article

作者: Chen, Lung-Ching ; Wang, Hong-Jaan ; Tang, Sung-Ling ; Hsu, Han-Lin ; Wu, Alexander T H ; Ansar, Muhamad ; Lee, Shih-Yu ; Kuo, Yu-Cheng ; Sumitra, Maryam Rachmawati ; Huang, Sheng-Liang ; Huang, Hsu-Shan ; Lawal, Bashir

Ovarian cancer remains the third most prevalent and deadliest gynecologic malignancy worldwide, with most patients eventually developing resistance to platinum-based chemotherapy. This highlights a critical unmet need for innovative multitargeted therapies to address current treatment challenges. In this study, we identified 35 differentially expressed genes (DEGs) through integrated analysis of four GEO ovarian cancer datasets, with validation using TCGA data. Gene Ontology (GO) and KEGG enrichment analyses highlighted key tumor-associated pathways, and protein-protein interaction (PPI) network modeling prioritized CDK1 and TTK as high-value therapeutic targets. We evaluated the association between molecular genomic features and drug responses across the NCI-60 ovarian cancer cell line panel (IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, NCI/ADR-RES, and SK-OV-3), using a series of salicylanilide-derived compounds and four FDA-approved drugs (cabozantinib, paclitaxel, rapamycin, and niclosamide) from the NCI Developmental Therapeutics Program (DTP). Among these, NSC765690 (MCC22) emerged as the most promising candidate. It demonstrated potent antiproliferative activity, high target selectivity, and strong binding affinity to both CDK1 and TTK. Multi-omics integration, combined with AI-driven network modeling, further elucidated NSC765690's mechanism of action and its relevance to ovarian cancer pathogenesis. Additionally, ADMET and pharmacokinetic profiling confirmed its favorable drug-like properties and low predicted toxicity. Collectively, these findings establish NSC765690 as a potent dual-target inhibitor and exemplify a rational, data-driven drug discovery pipeline for overcoming chemotherapy resistance in ovarian cancer.

2025-07-01·NEOPLASIA

Response of GEM models of neuroblastoma to cabozantinib assessed by multiparametric magnetic resonance imaging

Article

作者: King, Philippa ; Miranda, Susana ; Hallsworth, Albert ; Chesler, Louis ; Popov, Sergey ; Pearson, Andrew D J ; Jamin, Yann ; Almeida, Gilberto S ; Robinson, Simon P ; Webber, Hannah ; Yogev, Orli

BACKGROUND:

In neuroblastoma MYCN amplification is associated with enhanced angiogenesis and poor survival. Mutations in the anaplastic lymphoma kinase (ALK) gene can occur with MYCN amplification, conferring a very poor prognosis. Vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF)/c-MET signalling are implicated in neuroblastoma progression. Cabozantinib has potent activity against VEGFR2 and MET.

METHODS:

The efficacy of cabozantinib against tumours arising in GEM models of high-risk neuroblastoma was assessed using multiparametric MRI. Tumour-bearing Th-MYCN and Th-ALK^F1174L/Th-MYCN mice were imaged prior to, 24 and 48 hrs after treatment with either 30mg/kg/day cabozantinib or vehicle. Treatment-induced changes in tumour volume, native T₁, R₂* and ADC were evaluated, and histological correlates sought. Additional Th-MYCN mice were treated daily for up to 28 days.

RESULTS:

Cabozantinib elicited significant 24 and 60 % growth delay 24 and 48 hrs after treatment in tumours in Th-MYCN mice, and a significant 6-8 % reduction in native T₁. Tumour R₂* was significantly reduced 48 hrs post-treatment. Significantly higher tumour necrosis and apoptosis, and significantly lower Ki67, CD34 and VEGFR2 staining, was determined from the cabozantinib-treated mice. Treatment of Th-ALK^F1174L/Th-MYCN mice caused significant 4 % and 21 % tumour growth delay, and a significant 5 % reduction in native T₁ at 48 hrs. Daily cabozantinib treatment of Th-MYCN mice elicited significant tumour growth delay over 7 days which translated into significant survival benefit.

CONCLUSION:

Cabozantinib exhibits activity against neuroblastomas arising in both Th-MYCN and Th-MYCN/ALK^F1174L mice, revealed in situ using MRI. Native T₁ is an early, sensitive and clinically translatable imaging biomarker of effective treatment response in neuroblastoma.

682

项与苹果酸卡博替尼相关的新闻（医药）

2025-07-01

·ioncology

ESMO GI 2025明日启幕，中国消化道肿瘤前沿声音响彻巴塞罗那

编者按：2025年7月2日-5日，欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于西班牙巴塞罗那盛大召开，汇聚全球消化道领域最新诊疗观念与进展，包括704篇讲题和427篇壁报。此次会上，中国学者贡献了39项讲题，其中包括2项最新突破性摘要（LBA）、2项微型口头报告（MO）、1项教育主题汇报（Education Session）和34篇壁报（Poster）。现将中国之声整理如下，以飨读者。最新突破性摘要（LBA）摘要号：LBA1研究名称：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND TrialFIND试验中期分析：ctDNA甲基化动态监测指导非转移性结直肠癌术后随访讲者：彭俊杰 | 复旦大学附属肿瘤医院会场：Room Madrid时间：7月4日 16:30 - 16:40（当地时间）摘要号：LBA2研究名称：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC)TALENTACE研究：比较按需TACE联合阿替利珠单抗+贝伐珠单抗(Atezo+Bev)与单纯按需TACE治疗未经系统治疗的中高肿瘤负荷不可切除肝细胞癌（uHCC）的III期开放标签随机对照研究讲者：韩国宏 | 西安国际医学中心医院会场：Room Barcelona时间：7月3日 14:50 - 15:00（当地时间）微型口头报告（Mini Oral）摘要号：149MO研究名称：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 StudyABSK-011-201研究II期最新结果：依帕戈替尼（ABSK-011）联合阿替利珠单抗用于FGF19过表达型晚期肝细胞癌（HCC）的一线治疗及用于经免疫检查点抑制剂（ICIs）治疗患者的疗效分析讲者：程琪 | 华中科技大学同济医学院附属同济医院会场：Room Barcelona时间：7月2日 17:15 - 17:20（当地时间）摘要号：150MO研究名称：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosisSIERRA研究IIIb期安全性分析：度伐利尤单抗（D）联合替西木单抗（T）一线治疗伴临床预后不良特征的肝细胞癌（HCC）患者讲者：Stephen L. Chan | 香港中文大学会场：Room Barcelona时间：7月2日 17:20 - 17:25（当地时间）教育专题会（Education Session）讲题：New medical treatment in 2025 beyond IO combinations2025年突破免疫联合疗法的新兴医学治疗方向讲者：Stephen L. Chan | 香港中文大学会场：Room Madrid时间：7月3日 12:00 - 12:20（当地时间）壁报（Poster）01结直肠癌摘要号：11P研究名称：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I StudyNALIRIFOX联合靶向治疗一线治疗转移性结直肠癌的I期研究讲者：Haojie Zhou | 复旦大学附属中山医院摘要号：49P研究名称：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer转移性结直肠癌一线诱导治疗后维持策略与治疗间歇的多中心倾向性评分匹配比较研究讲者：Ka Yan Lai | 伊利沙伯医院摘要号：65P研究名称：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal CancerBETTER研究：替雷利珠单抗+贝伐珠单抗+TAS102+SBRT三线治疗MSS/pMMR转移性结直肠癌的开放标签单臂试验讲者：张群 | 南京鼓楼医院摘要号：98P研究名称：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth一种预测早期结直肠癌浸润深度的整合分子标志物的新型风险分层模型讲者：Bing Li | 复旦大学附属中山医院摘要号：130eP研究名称：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer从循证到实践：MSS/MSI-L结直肠癌免疫治疗的多中心真实世界研究与Meta分析讲者：Yue T. Gou | 中南大学湘雅医院摘要号：131eP研究名称：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment贝伐珠单抗+奥沙利铂+伊立替康三联方案治疗氟尿嘧啶经治转移性结直肠癌的疗效与安全性讲者：韩璐 | 中国人民解放军总医院第五医学中心摘要号：139eP研究名称：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)中国结直肠癌MSI/MMR检测与治疗实践全国调研（SUMMER研究）讲者：王正航 | 北京大学肿瘤医院摘要号：146TiP研究名称：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progressMIRACLE3研究：依沃西单抗联合放化疗一线治疗MSS型不可切除肝/肺转移结直肠癌的II期试验（进行中）讲者：李心翔 | 复旦大学附属肿瘤医院摘要号：224P研究名称：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)SPRING-01研究：短程放疗序贯信迪利单抗+CAPOX全直肠新辅助治疗局部进展期直肠癌的前瞻性随机对照试验讲者：田锋 | 山东第一医科大学附属省立医院摘要号：226P研究名称：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results阿得贝利单抗+短程放疗+CAPOX全新辅助治疗pMMR局部进展期直肠癌的中期分析讲者：靖昌庆 | 山东第一医科大学附属省立医院摘要号：229P研究名称：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)高风险局部进展期直肠癌新辅助放化疗±FOLFOXIRI强化治疗的随机研究：临床与生存质量分析（NCT03997435）讲者：Ka Yan Lai | 伊利沙伯医院02肝胆胰肿瘤摘要号：157P研究名称：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analysesCheckMate 9DW研究拓展分析：纳武利尤单抗联合伊匹木单抗 vs 仑伐替尼或索拉非尼一线治疗中国不可切除/晚期肝细胞癌患者讲者：秦叔逵 | 中国药科大学附属南京天印山医院摘要号：183P研究名称：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population中性粒细胞-淋巴细胞比值（NLR）与PLR、LMR、SII、PNI在肝癌冷冻消融术患者中的预后价值比较及最佳适用人群探索讲者：李家平 | 中山大学附属第一医院摘要号：195P研究名称：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinomaCOVID-19、肝硬化与肝细胞癌关联机制的生物信息学与系统生物学研究讲者：Xianxiang Chen | 广西医科大学第一附属医院摘要号：203eP研究名称：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis基于cfDNA生物标志物与人工智能模型的肝癌早期筛查：系统评价与Meta分析讲者：Minh Le | 台北医学大学摘要号：206eP研究名称：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib基线ALBI分级对接受仑伐替尼治疗的肝细胞癌患者预后的影响讲者：商昌珍 | 中山大学孙逸仙纪念医院摘要号：209eP研究名称：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT MechanismRPL41通过转录因子RUNX2介导的上皮间质转化（EMT）机制促进肝细胞癌转移讲者：Zheng A. Hua | 重庆大学附属沙坪坝医院摘要号：302P研究名称：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer索凡替尼联合吉西他滨及白蛋白结合型紫杉醇用于可切除/临界可切除胰腺癌新辅助治疗讲者：高松 | 天津市肿瘤医院摘要号：313P研究名称：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancerABHD17C介导的BCL6B蛋白S-去棕榈酰化通过激活CD24转录抵抗胰腺癌巨噬细胞吞噬讲者：Yalu Zhang | 中国科学技术大学附属第一医院摘要号：317P研究名称：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity肿瘤微环境芯片：异质性下免疫治疗疗效的实时观测窗口讲者：Chiao-Min Lin | 台湾清华大学摘要号：358P研究名称：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study胆道癌根治术后辅助化疗方案的疗效比较：单中心回顾性队列研究讲者：Wen-Ying Lin | 台北荣民总医院03胃食管癌摘要号：394P研究名称：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials卡瑞利珠单抗为基础治疗食管鳞癌的反应性皮肤毛细血管内皮增生（RCCEP）：两项III期试验的合并分析讲者：骆卉妍 | 中山大学肿瘤防治中心摘要号：396P研究名称：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy卡博替尼联合阿替利珠单抗用于含铂化疗失败的复发/转移性食管鳞癌（R/M ESCC）患者：单臂II期研究讲者：Hung-Yang Kuo | 台湾大学医学院附设医院摘要号：399P研究名称：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic ReprogrammingARL5B通过ROCK1-SREBP1介导代谢重编程驱动食管鳞癌进展的机制研究讲者：Xinyue Ma | 山东大学齐鲁医院摘要号：418P研究名称：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study纳武利尤单抗一线治疗晚期胃/胃食管结合部腺癌的真实世界研究结局：多中心回顾性观察研究讲者：邱红 | 华中科技大学同济医学院附属同济医院摘要号：419P研究名称：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)SURPASS研究：中国晚期胃/胃食管结合部癌（GC/GEJC）真实世界治疗模式与生物标志物检测现状调研讲者：Rongrui Liu | 中国人民解放军总医院摘要号：424P研究名称：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study化疗（SOX）联合替雷利珠单抗治疗胃癌肝转移：一项多中心II期研究的首次报告讲者：康牧星 | 浙江大学医学院附属第二医院摘要号：430P研究名称：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical TrialCLDN18.2特异性CAR-T细胞（CT041）治疗胃癌的应答与耐药特征解析：I期临床试验探索性生物标志物分析讲者：彭浩欣 | 北京大学肿瘤医院摘要号：436P研究名称：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions肝切除改善原发性病灶切除的胃癌肝转移患者预后讲者：Yun Feng | 复旦大学附属肿瘤医院04其他摘要号：219eP研究名称：Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study转移性胃肠间质瘤行肿瘤细胞减灭术的预后因素分析：一项回顾性队列研究讲者：Haidong Zhang | 四川大学华西医院摘要号：495P研究名称：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction初始剂量减量策略改善老年胃肠道肿瘤患者化疗耐受性的优化研究讲者：Wendy W. Chan | 香港玛丽医院摘要号：499P研究名称：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapyTACR1基因型与含奥氮平止吐方案防治化疗相关性呕吐的疗效关联研究讲者：Winnie Yeo | 香港中文大学摘要号：505eP研究名称：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers安罗替尼治疗贝伐珠单抗经治胃肠道肿瘤的真实世界疗效讲者：陈锦章 | 南方医科大学南方医院摘要号：506eP研究名称：Impact of CARG-Guided Dose Adjustment of Anticancer Therapy on Adverse Events in Chinese Elderly Cancer Patients: A Prospective Study基于CARG评估指导抗肿瘤治疗剂量调整对中国老年癌症患者不良事件的影响：前瞻性研究讲者：葛郁平 | 北京协和医院（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床3期临床2期免疫疗法临床结果

2025-07-01

·肿瘤界

2025 ESMO GI | 中国智慧闪耀国际：入选研究一览

点击蓝字关注我们前言一年一度的欧洲肿瘤内科学会胃肠肿瘤年会（ESMO GI）将于2025年7月2日~5日在巴塞罗那召开。日前，大会官网披露了摘要标题，其中34项中国研究入选。整理如下，和您一起先睹为快！胃食管癌1摘要号：394P研究名称（英文）：Reactive cutaneous capillary endothelial proliferation in esophageal squamous cell carcinoma patients treated with camrelizumab-based therapy: a pooled analysis of two phase 3 trials 讲者：骆卉妍 | 中山大学肿瘤防治中心2摘要号：396P研究名称（英文）：A single-arm phase II study of cabozantinib and atezolizumab in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M ESCC) who failed platinum-based chemotherapy 讲者：Hung-Yang Kuo | 台湾大学医学院附设医院3摘要号：399P研究名称（英文）：ARL5B Drives Esophageal Squamous Cell Carcinoma Progression via ROCK1-SREBP1 Mediated Metabolic Reprogramming 讲者：Xinyue Ma | 山东大学齐鲁医院4摘要号：418P研究名称（英文）：Real-world Outcomes of First-line Nivolumab for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: A Multicenter, Retrospective, Observational Study 讲者：邱红 | 华中科技大学同济医学院附属同济医院5摘要号：419P研究名称（英文）：Real-world Treatment Pattern and Biomarker Testing Landscape of Advanced Gastric/Gastroesophageal Junction Cancer (GC/GEJC) in China (SURPASS Study)讲者：Rongrui Liu | 中国人民解放军总医院6摘要号：424P研究名称（英文）：Chemotherapy (SOX) plus Tisleizumab in Gastric cancer patients with liver metastasis: the first report from a multi-center phase II study 讲者：康牧星 | 浙江大学医学院附属第二医院7摘要号：430P研究名称（英文）：Decoding the Responsive and Resistant Features to the Claudin18.2-specific CAR-T cell CT041 in Gastric Cancer: An Exploratory Biomarker Analysis of the Phase 1 Clinical Trial 讲者：彭昊昕 | 北京大学肿瘤医院8摘要号：436P研究名称（英文）：Hepatic resection improves the prognosis of gastric cancer liver metastasis patients with resected primary lesions讲者：Yun Feng | 复旦大学附属肿瘤医院肝胆胰肿瘤1摘要号：LBA2研究名称（英文）：TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization (TACE) combined with atezolizumab + bevacizumab (Atezo+Bev) or on-demand TACE alone in patients with systemically untreated, intermediate-to-high burden unresectable hepatocellular carcinoma (uHCC) 讲者：韩国宏 | 西安国际医学中心医院2摘要号：149MO研究名称（英文）：Irpagratinib (ABSK-011) plus Atezolizumab in First-line (1L) and Immune Checkpoint Inhibitors (ICIs) Treated Advanced Hepatocellular Carcinoma (HCC) with FGF19 Overexpression (+): Updated Results of the Phase 2 ABSK-011-201 Study讲者：程琪 | 华中科技大学同济医学院附属同济医院3摘要号：150MO研究名称（英文）：Safety results from the Phase 3b SIERRA study of durvalumab (D) and tremelimumab (T) as first-line (1L) treatment (tx) for hepatocellular carcinoma (HCC) participants (pts) with a poor prognosis讲者：Stephen L. Chan | 香港中文大学4摘要号：157P研究名称（英文）：Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line (1L) treatment in Chinese patients with unresectable/advanced hepatocellular carcinoma (HCC): CheckMate 9DW expanded analyses 讲者：秦叔逵 | 中国药科大学附属南京天印山医院5摘要号：183P研究名称（英文）：Comparison of the prognostic value of NLR with PLR, LMR, SII, and PNI in HCC patients undergoing cryoablation and its application in the best applicable population讲者：李家平 | 中山大学附属第一医院6摘要号：195P研究名称（英文）：Bioinformatics and system biology approach to identify the influences among COVID-19, cirrhosis and hepatocellular carcinoma讲者：Xianxiang Chen | 广西医科大学第一附属医院7摘要号：203eP研究名称（英文）：Cell-free DNA (cfDNA) Biomarkers and AI Models for Early Detection of Liver Cancer: A Systematic Review and Meta-Analysis讲者：Minh Le | 台北医学大学8摘要号：206eP研究名称（英文）：Prognostic Influence of Baseline ALBI Grade on Treatment Outcomes in Hepatocellular Carcinoma Patients Receiving Lenvatinib讲者：商昌珍 | 中山大学孙逸仙纪念医院9摘要号：209eP研究名称（英文）：RPL41 Promotes HCC Metastasis Via Transcription Factors RUNX2-Mediated EMT Mechanism讲者：Zheng Hua | 重庆大学附属沙坪坝医院10摘要号：302P研究名称（英文）：Surufatinib plus gemcitabine and nab-paclitaxel for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer讲者：高松 | 天津市肿瘤医院11摘要号：313P研究名称（英文）：ABHD17C-mediated S-depalmitoylation of BCL6B enhances CD24 transcription to resist macrophage phagocytosis in pancreatic cancer讲者：Yalu Zhang | 中国科学技术大学附属第一医院12摘要号：317P研究名称（英文）：Tumor-Microenvironment-on-Chip: A Real-Time Window into Immunotherapy Efficacy under Heterogeneity讲者：Chiao-Min Lin | 台湾清华大学13摘要号：358P研究名称（英文）：Comparative Effectiveness of Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancer: A Single-Center Retrospective Cohort Study讲者：Wen-Ying Lin | 台北荣民总医院结直肠癌1摘要号：LBA1研究名称（英文）：Dynamic Circulating Tumor DNA Methylation Monitoring Guiding Postoperative Surveillance in Non-Metastatic Colorectal Cancer: Interim Analysis of FIND Trial讲者：彭俊杰 | 复旦大学附属肿瘤医院2摘要号：11P研究名称（英文）：NALIRIFOX Plus Targeted Therapy as First-Line Treatment for Metastatic Colorectal Cancer: A Phase I Study讲者：Haojie Zhou | 复旦大学附属中山医院3摘要号：49P研究名称（英文）：A multicentre propensity score matched analysis comparing maintenance strategies and treatment-break after first-line induction therapy for metastatic colorectal cancer讲者：Connie Ka Yan Lai | 伊利沙伯医院4摘要号：65P研究名称（英文）：BETTER Study: An Open-Label, Single-Arm Trial of Tislelizumab, Bevacizumab, TAS102, and SBRT as Third-Line Therapy for MSS/pMMR Metastatic Colorectal Cancer 讲者：张群 | 南京鼓楼医院5摘要号：98P研究名称（英文）：A novel risk-stratification model with molecular markers for predicting early colorectal cancer invasion depth讲者：Bing Li | 复旦大学6摘要号：130eP研究名称（英文）：From Evidence to Practice: A Multicenter Real-World Study and Meta-Analysis of Immunotherapy in MSS/MSI-L Colorectal Cancer讲者：Yue Gou | 中南大学7摘要号：131eP研究名称（英文）：Efficacy and safety of triple-therapy with bevacizumab, oxaliplatin, with irinotecan for metastatic colorectal cancer failed with previous fluorouracil-centered treatment讲者：韩璐 | 中国人民解放军总医院第五医学中心8摘要号：139eP研究名称（英文）：Real-World Practice of MSI/MMR Testing and Treatment Patterns in Colorectal Cancer: A Nationwide Survey in China (SUMMER Study)讲者：王正航 | 北京大学肿瘤医院9摘要号：146TiP研究名称（英文）：MIRACLE3: Phase II study of Ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases — Trial in progress讲者：李心翔 | 复旦大学附属肿瘤医院10摘要号：224P研究名称（英文）：Short-course radiotherapy followed by sintilimab and CAPOX as total neoadjuvant treatment in locally advanced rectal cancer: a prospective, randomized controlled trial (SPRING-01)讲者：Feng Tian | 山东第一医科大学附属省立医院11摘要号：226P研究名称（英文）：Adebrelimab Combined with Short-Course Radiotherapy and CAPOX as Total Neoadjuvant Therapy for pMMR Locally Advanced Rectal Cancer: Interim Results讲者：靖昌庆 | 山东第一医科大学附属省立医院12摘要号：229P研究名称（英文）：Randomized study of neoadjuvant chemoradiotherapy with or without intensification with FOLFOXIRI for high-risk locally advanced rectal cancer - clinical and quality of life analysis (NCT03997435)讲者：Ka Yan Lai | 伊利沙伯医院胃肠道罕见肿瘤1摘要号：219eP研究名称（英文）：Prognostic Factors for Metastatic Gastrointestinal Stromal Tumors Treated with Cytoreductive Surgery: A Retrospective Cohort Study 讲者：Haidong Zhang | 四川大学华西医院其他1摘要号：495P研究名称（英文）：Optimising Chemotherapy Tolerability in Older Gastrointestinal Cancer Patients with Initial Dose Reduction讲者：Wendy W. Chan | 香港大学李嘉诚医学院2摘要号：499P研究名称（英文）：Association of TACR1 genotype and response to olanzapine-containing antiemetic prophylaxis for chemotherapy讲者：Winnie Yeo | 香港中文大学3摘要号：505eP研究名称（英文）：Real World Efficacy of Anlotinib in Bevacizumab-Treated Gastrointestinal Cancers讲者：陈锦章 | 南方医科大学南方医院备注：如有遗漏或任何问题，请给我们留言~声明：本文由“肿瘤界”整理与汇编，欢迎分享转载，如需使用本文内容，请务必注明出处。来源：医脉通消化系统肿瘤编辑：lagertha审核：南星

临床结果细胞疗法临床2期免疫疗法

2025-06-26

·CityofHope希望之城

ASCO 2025 特辑｜全球专家对话：从临床试验到肾癌治疗新突破

2025年5月30日至6月3日，美国临床肿瘤学会（ASCO）年会在芝加哥顺利召开，吸引了全球近45,000名肿瘤学专家齐聚一堂，共同交流癌症研究与治疗的前沿进展。作为美国顶尖五大癌症中心之一的希望之城（City of Hope），其研究团队在本届 ASCO 年会上带来了最前沿的科研数据及最新成果，助力医疗团队为患者提供更加个性化且高效的生命救治方案。本文汇总了两场来自ASCO年会现场对希望之城肿瘤内科主任 Sumanta Kumar Pal 博士的深度对话：第一场由巴西阿尔伯特·爱因斯坦医院主持，深入探讨了临床试验的意义与挑战；第二场由中国领先医学媒体医脉通及北京大学肿瘤医院盛锡楠教授主持，聚焦于肾癌治疗领域的策略革新。通过两场对话，我们得以深入理解精准医疗的最新趋势，以及临床研究在推动癌症治疗中的关键角色。临床研究如何重塑治疗路径：来自爱因斯坦医院与希望之城的对话在ASCO年会现场，来自阿尔伯特·爱因斯坦医院的肿瘤科医生Diogo Bugano与Andrey Soares医生，与希望之城Pal博士共同探讨了临床研究对患者和国家肿瘤治疗进步的重要意义。近年来，全球癌症临床试验数量迅速上升，从2019年的6.3万个增长至2024年的超过11万个。Pal 博士指出，这一趋势反映出全球医疗界在推动新疗法落地方面的努力，尤其是细胞治疗技术的应用——包括 CAR-T 细胞疗法与肿瘤浸润性淋巴细胞（TIL）治疗，已在多个癌种中展现希望。细胞疗法本质上属于免疫治疗的一种，通过激活免疫系统靶向攻击肿瘤细胞。近年来，抗体偶联药物（ADCs）和核素标记抗体等新型精准疗法的出现，正在为肿瘤治疗带来新的可能。这些“精准导弹”般的疗法能够减少毒副作用、提高靶向效率，特别是在泌尿系统肿瘤中已初见成效。然而，Pal 博士强调，疗效的关键在于明确靶点。这正是精准医学时代的核心——基因检测、蛋白表达谱分析等手段，让医生能为患者量身定制治疗方案。他指出，“我治疗过的长期生存患者，几乎都曾参与临床试验。”在实际诊疗中，如何将试验机会与日常治疗结合，成为医生面临的重要议题。爱因斯坦医院医生认为，巴西患者对临床试验仍存误解，需加强科普。实际上，大多数临床试验在开展前已通过动物与早期人群验证，安全性已有保障。而患者参与试验不仅无需承担治疗费用，还有机会率先接触潜在改变治疗标准的新药。临床研究的意义还体现在医生与医疗机构自身能力的提升上。参与国际多中心试验的医生能不断更新知识体系，与全球专家协作，从而为患者提供更先进的治疗。同时，Pal 博士也提到，希望之城与爱因斯坦医院之间已有多年深度合作，未来将在人员交流与临床试验设计方面持续拓展，为不同地区患者带来更多治疗机会。生物标志物与辅助治疗：推动肾癌精准治疗再进阶在另一场由医脉通主持的现场对话中，Pal 博士与北京大学肿瘤医院盛锡楠教授共同探讨了肾癌治疗的最新策略，重点关注生物标志物、辅助免疫治疗及治疗方案的个体化选择。Pal博士专注于肾癌领域的临床诊疗工作已逾20年。他主持了多项II期和III期临床试验，在肾癌治疗的未知领域中不断探索前行。近期，Pal博士将研究目光聚焦于细胞治疗和双特异性抗体等创新疗法的临床研究。在肾癌治疗领域，传统的治疗方法虽取得了一定成效，但面对复杂多变的病情和患者的个体差异，仍存在诸多局限。他指出，当前肾癌治疗正处于关键转折期，治疗模式仍然需要不断革新。Pal 博士（左）与盛锡楠教授（右）生物标志物探索：开启肾癌精准治疗新钥匙在肾癌治疗中，生物标志物犹如一把把精准的钥匙，能够帮助医生打开个性化治疗的大门。Sumanta Kumar Pal博士在ASCO年会上发表的IMmotion010研究，在生物标志物的探索方面取得了重要进展。该研究评估了阿替利珠单抗作为肾细胞癌（RCC）患者术后辅助治疗的疗效，尽管阿替利珠单抗辅助治疗并未显著延长复发风险较高的RCC患者在接受肾切除术后的无病生存期（DFS），但蛋白质组学分析却带来了令人惊喜的发现。肾损伤分子-1(KIM-1）在复发时收集的样本中显著富集，且既往研究显示基线KIM-1水平较高的患者在接受阿替利珠单抗治疗后的DFS优于接受安慰剂治疗的患者。这一发现提示KIM-1或可作为预测阿替利珠单抗疗效的生物标志物。Sumanta Kumar Pal博士及其团队通过TruSeq RNA存取技术生成全转录组谱，并运用随机森林算法推导出标志物评分及NMF1-7亚型，在单纯亚组、KIM-1高表达组（KIM-1H）以及低表达组（KIM-1L）中评估患者临床结局，最终证实血清KIM-1水平是预测阿替利珠单抗治疗效果的最有力指标。这一研究成果为肾癌的精准治疗提供了新的思路。作为阿替利珠单抗生产商罗氏公司的有偿顾问，Pal博士兴奋地说道：“KIM-1 是目前预测阿替利珠单抗疗效最可靠的生物标志物。我们通过对患者使用阿替利珠单抗前及复发后的肾癌组织进行全转录组测序，揭示了疾病进展中的基因组演化规律，这为理解肾癌复发机制提供了新视角。进一步明确这些生物标志物将助力临床医生为肾癌患者制定更精准的治疗方案。” “我们将继续研究肾癌患者的遗传学特征，以期通过这些发现延长患者生命。本研究基于生物标志物 KIM-1，通过分析肿瘤基因组特征，可筛选出能从阿替利珠单抗辅助治疗中获益的肾癌患者。” Pal博士继续说道。应对治疗耐药性：探寻个体化治疗新策略Sumanta Kumar PalM.D., F.A.S.C.O.肾癌治疗的耐药性问题一直是困扰医生和患者的难题。在之前的一项针对晚期RCC的独立III期研究（IMmotion151）中，Pal博士及其团队通过非负矩阵分解（NMF）确立了7个分子亚组，并重点观察了这些亚型。研究发现，患者产生治疗耐药性的机制存在多样性，每位肾癌患者可能都存在独特的耐药机制。接受阿替利珠单抗治疗后产生耐药的患者，其肿瘤组织的MHC-1特征普遍减弱，这提示MHC - 1通路下调可能是检查点抑制剂耐药的一个潜在机制。这一发现为解决治疗耐药性问题提供了新的靶点。未来，或许可以针对MHC - 1通路探索新的治疗策略，例如开发能够增强MHC - 1表达的药物，或者采用联合治疗的方式，克服耐药性，提高治疗效果。同时，这也提醒医生在治疗过程中要密切关注患者的病情变化，及时调整治疗方案，实现个体化治疗。辅助治疗策略优化：为肾癌患者保驾护航针对具有复发风险的T1/T2期患者，Pal博士提出了基于KIM-1生物标志物的潜在辅助治疗策略。鉴于帕博利珠单抗的明确生存获益，未来或可通过KIM-1识别早期辅助免疫治疗获益人群，即理论复发风险较低（如T1/低级别T2期）但KIM-1表达显著升高的患者，此类群体可能成为干预的关键目标。对于肾癌患者术后多年出现孤立性肺转移这类特殊患者，Pal博士认为基于现行标准，多年未复发的肾癌患者通常不推荐进行辅助治疗。但需重点关注是否存在KIM-1高表达的特定亚群，若该亚群存在，需通过研究验证其能否为选择性辅助治疗提供理论依据。转移性肾细胞癌治疗选择：平衡疗效与安全性在转移性肾细胞癌（mRCC）的治疗中，FDA已批准多种联合治疗方案，如何为患者选择最佳治疗方案是临床医生面临的重要问题。Pal博士基于当前的临床数据，对不同治疗方案进行了深入分析。他认为阿昔替尼联合帕博利珠单抗方案的临床获益相对有限，较少将其作为优选方案；仑伐替尼联合帕博利珠单抗方案虽然疗效有一定潜力，但不良反应较为显著，限制了其临床应用；而卡博替尼联合纳武利尤单抗方案在疗效与安全性之间取得了较为理想的平衡，成为他在临床实践中优先考虑的方案之一。对于低危患者，Pal博士通常会优先选择卡博替尼联合纳武利尤单抗方案；而对于中高危患者，则会根据患者的具体情况，在卡博替尼联合纳武利尤单抗方案与纳武利尤单抗联合伊匹木单抗方案之间进行个体化的选择。对于保留原发肾脏且未行手术的患者，他倾向于选择纳武利尤单抗联合伊匹木单抗方案，以保留患者后续接受手术治疗的可能性，并在术前维持治疗的连续性。这种个体化的治疗策略充分考虑了患者的病情、身体状况和治疗需求，能够更好地平衡治疗效果与安全性，为mRCC患者提供更精准的治疗方案。减瘤性手术抉择：科学权衡利弊在初诊患者的治疗决策中，何时选择减瘤性手术是一个极具价值的问题。Pal博士指出，目前尚未有确切的答案，但存在高钙血症、副肿瘤综合征以及严重的疼痛或出血这三种情况需要考虑切除肾脏。在当前的临床实践中，除了参与临床试验外，他的常规做法是优先采用全身系统性治疗，仅在出现上述情况或在其他转移灶得到充分控制之后，才会考虑手术切除肾脏。Pal博士还提到了正在开展的“PROBE”临床试验，该试验将患者随机分配到接受手术组或不接受手术组，随后开始相应的治疗。尽管这项研究具有重要意义，但病例积累速度较为缓慢，能否获得令人满意的答案尚不确定。这一现状反映了减瘤性手术抉择的复杂性和不确定性，需要更多的临床研究来提供科学依据。二线治疗探索：为患者寻找新希望在中国mRCC二线治疗尚未形成标准化方案的背景下，Pal博士分享了他的专业建议。在二线治疗中，他通常优先选择卡博替尼，若无法获得卡博替尼，则会考虑使用阿昔替尼或其他TKI。对于未来可能使用的贝组替凡，他持相对谨慎的态度，因为观察到其起效速度可能相对较慢，而患者在经过一至二线治疗后，肿瘤往往进展迅速。细胞治疗展望：开启肾癌治疗新时代在肾癌治疗领域，传统的治疗方法面临着诸多挑战，亟需开发新药。Pal博士对CAR - T细胞治疗等创新疗法寄予厚望。目前mRCC主要依赖VEGF抑制剂等靶向治疗或免疫疗法，而CAR - T细胞疗法为肾癌治疗带来了新的希望。Pal 博士在肾癌领域的研究历程充满了探索与创新。他始终坚信，临床试验不仅是推动新药研发的核心途径，更是为患者提前接触变革性疗法、赢得生存希望的重要机会。无论是在生物标志物的深入挖掘、治疗耐药性的机制解析，还是在辅助与转移性治疗策略的优化、减瘤性手术与二线治疗路径的探索中，Pal博士都体现了卓越的科研能力与临床远见。随着细胞治疗等前沿疗法不断取得突破，他所倡导并实践的以临床研究为核心的精准医疗，正引领肾癌治疗迈向全新阶段，为更多患者带来转机与希望。

ASCO会议免疫疗法细胞疗法

100 项与苹果酸卡博替尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10095	苹果酸卡博替尼	L01XE26	DB08875

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
胰腺外神经内分泌肿瘤	美国	Exelixis, Inc.	2025-03-26
胰腺神经内分泌肿瘤	美国	Exelixis, Inc.	2025-03-26
分化型甲状腺癌	韩国	Ipsen Ltd.	2017-09-26
肾细胞癌	韩国	Ipsen Ltd.	2017-09-26
肝细胞癌	欧盟	Ipsen Pharma SAS	2016-09-09
肝细胞癌	冰岛	Ipsen Pharma SAS	2016-09-09
肝细胞癌	列支敦士登	Ipsen Pharma SAS	2016-09-09
肝细胞癌	挪威	Ipsen Pharma SAS	2016-09-09
晚期肾细胞癌	美国	Exelixis, Inc.	2016-04-25
甲状腺髓样癌	美国	Exelixis, Inc.	2012-11-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
实体瘤	申请上市	中国	江苏豪森药业集团有限公司	2020-09-28
难治性分化型甲状腺癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2024-08-22
难治性甲状腺癌	临床3期	美国	ECOG-ACRIN Medical Research Foundation, Inc.	2024-08-22
转移性骨肉瘤	临床3期	美国	National Cancer Institute	2023-03-03
晚期尿路上皮癌	临床3期	美国	National Cancer Institute	2022-06-03
晚期尿路上皮癌	临床3期	加拿大	National Cancer Institute	2022-06-03
膀胱癌	临床3期	美国	National Cancer Institute	2022-06-03
膀胱癌	临床3期	加拿大	National Cancer Institute	2022-06-03
转移性尿道尿路上皮癌	临床3期	美国	National Cancer Institute	2022-06-03
转移性尿道尿路上皮癌	临床3期	加拿大	National Cancer Institute	2022-06-03

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05536141 (ARC-20, PipelineReview) 人工标引	临床1期	肾细胞癌	42	Casdatifan 100mg QD + Cabozantinib 60mg QD	鹹窪願網憲鬱鬱網糧範(鬱簾壓憲網鏇鏇觸顧襯) = 築蓋糧壓齋選鏇顧遞艱淵鹽鏇範齋顧憲願蓋夢 (蓋製廠艱醖膚鬱繭壓鹽, 26 ~ 67) 更多	积极	2025-06-02
NCT05536141 (ARC-20, ASCO2025) 人工标引	临床1期	肾细胞癌	27	Casdatifan 100 mg + Cabozantinib 60 mg	蓋廠觸衊艱遞壓窪鹹壓(網衊觸襯鹽鹹鏇積夢醖) = 築構襯壓鏇蓋簾齋襯齋選鬱願夢糧醖鬱鬱範憲 (構淵遞簾艱範夢願夢遞 ) 更多	积极	2025-05-30
NCT04413123 (phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh), ASCO2025)	临床2期	晚期肾细胞癌	20	Cabozantinib 20 mg/d + Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg	簾網選築壓選壓鬱淵願(鬱鏇夢繭選範鹹憲簾顧) = 繭觸廠觸廠網壓鏇餘觸構齋繭鹹淵鬱選膚鹽鑰 (觸簾齋艱遞淵遞範夢遞, 13 ~ 41) 更多	积极	2025-05-30
CABONEN (ASCO2025)	临床2期	神经内分泌肿瘤 Ki67	45	Cabozantinib	繭築鹽範衊齋網廠遞製(醖膚觸觸構糧鏇構鏇觸) = 鑰範獵願簾壓襯醖積製鹽鏇壓壓鏇夢選網繭鬱 (壓壓鏇構顧鏇鹽艱繭鬱 ) 更多	积极	2025-05-30
NCT01639508 (phase II study of cabozantinib in patients with MET-altered lung cancers, ASCO2025)	临床2期	肺癌 MET exon 14 alterations \| MET amplification	28	Cabozantinib 60 mg daily	簾壓製選蓋鹹夢淵餘構(鹽選顧膚膚壓壓遞鹹鑰) = 簾構網鑰壓鹹鹹觸廠膚鏇鬱製醖壓襯願獵網遞 (獵鹽窪顧網壓鑰鏇夢簾, 8.9 ~ 39.1) 更多	积极	2025-05-30
NCT04338269 (CONTACT-03, ASCO2025)	临床3期	晚期肾细胞癌二线	522	Cabozantinib (cabo)	鹹鑰淵網積餘衊齋壓壓(遞糧襯繭壓齋淵顧網鬱) = 築網簾糧積鏇艱繭艱網衊構齋顧範積積鏇積積 (選鹹鹽衊鏇構鹹鏇範鹹 ) 更多	积极	2025-05-30
NCT04338269 (CONTACT-03, ASCO2025)	临床3期	晚期肾细胞癌二线	522	Cabozantinib (cabo) + Atezolizumab (atezo)	鹹鑰淵網積餘衊齋壓壓(遞糧襯繭壓齋淵顧網鬱) = 鑰鑰廠築餘壓顧繭選淵衊構齋顧範積積鏇積積 (選鹹鹽衊鏇構鹹鏇範鹹 ) 更多	积极	2025-05-30
ASCO2025	N/A	晚期肝细胞癌二线	552	Lenvatinib	網衊製鹹夢網簾築蓋壓(鬱簾糧憲襯獵膚淵艱艱) = 鹽糧願築願齋夢觸醖鬱艱鏇築鬱衊範鹽選鹹鏇 (觸壓膚餘蓋餘獵夢積夢 )	不佳	2025-05-30
ASCO2025	N/A	晚期肝细胞癌二线	552	Cabozantinib	網衊製鹹夢網簾築蓋壓(鬱簾糧憲襯獵膚淵艱艱) = 窪淵願選衊膚製鑰選醖艱鏇築鬱衊範鹽選鹹鏇 (觸壓膚餘蓋餘獵夢積夢 )	不佳	2025-05-30
NCT01441947 (CTgov)	临床2期	HR阳性乳腺癌	68	Cabozantinib (Cabozantinib)	選蓋選製憲壓憲選鏇簾 = 壓選夢選積範繭衊積鹹醖遞廠願醖窪繭製蓋願 (積選餘鬱積鹽製築鑰糧, 製鹽壓廠齋淵願構醖範 ~ 壓鹽襯餘衊鬱築顧壓襯) 更多	-	2025-05-25
NCT01441947 (CTgov)	临床2期	HR阳性乳腺癌	68	fulvestrant+Cabozantinib (Cabozantinib Plus Fulvestrant)	簾鹽願壓鏇膚繭鹽獵艱(範鹹鬱簾遞艱膚範淵艱) = 製範夢遞衊衊選構壓築製製鹽廠糧淵選鑰壓範 (糧餘鹹壓構築鹽壓鬱壓, 齋夢獵鏇願餘選鬱製積 ~ 選獵艱衊淵醖膚顧淵衊) 更多	-	2025-05-25
NCT03170960 (COSMIC-021, Pubmed \| J Clin Oncol)	临床1期	转移性尿路上皮癌一线 \| 一线	121	Cabozantinib 40 mg + Atezolizumab 1,200 mg	繭鑰觸積顧網夢憲鹽鏇(願鑰顧選構簾襯製構選) = 顧艱夢淵齋獵齋蓋選選糧鏇範製淵蓋鹹蓋鑰範 (齋積網簾鏇願願壓夢鹽, 15 ~ 49) 更多	积极	2025-05-10
NCT06026410 (FIT-001, AACR2025)	临床1期	肾细胞癌	-	Farnesyl transferase inhibitor KO-2806	構壓齋顧觸淵醖繭網淵(壓餘觸獵網遞窪鏇鏇艱) = 壓糧築積鑰獵遞繭糧構範獵遞膚衊襯鹽窪鹹壓 (範廠膚願壓糧網壓糧構 )	积极	2025-04-28
NCT06026410 (FIT-001, AACR2025)	临床1期	肾细胞癌	-	Cabozantinib	築鏇鹽簾鹽選範淵遞遞(構繭鹹齋襯襯壓遞鬱獵) = 醖獵壓齋艱鏇鏇鑰餘壓鬱糧窪夢網襯膚膚鑰製 (壓鹽襯積選衊簾膚製遞 )	积极	2025-04-28